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OBJECTIVES The goal of this research was to study the effects of rosuvastatin on systemic and regional
hemodynamics in two hypertensive rat models, one genetic, the other induced with inhibition
of nitric oxide synthesis.
BACKGROUND Rats naturally have low cholesterol levels that are generally unaffected by statin therapy, thus
providing a good model for studying cardiovascular effects unrelated to lipid metabolism.
METHODS Male 20-week-old spontaneously hypertensive rats (SHR) were divided into five groups and
given either vehicle or 1, 5, 10, and 20 mg/kg of rosuvastatin daily, by gavage, for 12 weeks.
Wistar-Kyoto rats (WKY) were divided into four groups; the first received vehicle and the
second rosuvastatin (20 mg/kg). The third and fourth groups were given N-nitro-L-arginine
(L-NAME) (15mg/kg/day) in drinking water, and the fourth group received rosuvastatin
daily, 20 mg/kg for six weeks. At the end of the respective treatments, systemic and organ
hemodynamics (radionuclide-labeled microspheres) and cardiovascular mass were determined
in all rats.
RESULTS Rosuvastatin reduced arterial pressure in SHR rats, but not in WKY/L-NAME rats. Total
peripheral resistance decreased with rosuvastatin in both hypertensive models, whereas
cardiac output increased with rosuvastatin in WKY/L-NAME rats. Neither cardiac nor aortic
mass was changed. Regional hemodynamics improved with rosuvastatin in both hypertensive
models, as evidenced by increased blood flows and decreased vascular resistances. No effect on
plasma lipids was observed.
CONCLUSIONS These results showed that rosuvastatin reduced arterial pressure in genetic hypertension and
improved systemic and regional hemodynamics in both hypertensive models independently of
cholesterol levels. Thus rosuvastatin improved systemic and regional hemodynamics by
reducing vascular resistance. (J Am Coll Cardiol 2003;42:1091–7) © 2003 by the American
College of Cardiology Foundation
There is accumulating evidence that 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors, or statins,
exert numerous beneficial effects that are apparently inde-
pendent of their action on blood lipids (1–3). These include
effects on the cardiovascular system, kidneys, bone, and
glucose metabolism. A number of clinical trials have shown
that statins significantly reduce cardiovascular morbidity
and mortality. Potential mechanisms that may mediate
beneficial cardiovascular action of statins include modula-
tion of endothelial function (4–7), anti-inflammatory action
(8,9), antioxidant properties (10), plaque stabilization (11),
and effects on thrombosis (12) and vasculogenesis (13). It is
also worth noting that, although statins share a common
lipid-lowering effect, there seem to be differences within this
class of drugs, not only in their lipid-lowering potential, but
also in their nonlipid effects (14). These potential differences
necessitate careful and systematic studies involving each
member of the statin family.
In the present study we examined cardiovascular effects of
rosuvastatin, a new HMG-CoA reductase inhibitor (15).
To this end, the effects of rosuvastatin on systemic and
regional hemodynamics were studied in spontaneously hy-
pertensive (SHR) rats, normotensive (Wistar-Kyoto; WKY)
rats, and in WKY in which endothelial function had been
compromised by the administration of N-nitro-L-arginine
(L-NAME) (16), an inhibitor of nitric oxide synthesis.
Because plasma lipid levels are normally low in rats (in
contrast with human beings) and because statins usually do
not modify lipid profile in rats, they provide an excellent
model for studying the other cardiovascular effects of statins.
METHODS
Animals. Adult male WKY and SHR rats were obtained
from Charles River Breeding Laboratories (Wilmington,
Massachusetts). They were housed in a temperature and
humidity controlled facility with 12 h light/dark cycle.
Standard rat chow (PMI Nutrition International, St. Louis,
Missouri) and tap water were provided ad libitum unless
stated otherwise. Our Institutional Animal Care and Use
Committee had approved the study in advance.
Experimental protocol. Two experiments were performed:
one in the SHR with naturally occurring hypertension and
From the Hypertension Research Laboratory, Ochsner Clinic Foundation, New
Orleans, Louisiana. Supported, in part, by a grant-in-aid by Astra-Zeneca Pharma-
ceuticals.
Manuscript received January 12, 2003; revised manuscript received May 19, 2003,
accepted June 5, 2003.
Journal of the American College of Cardiology Vol. 42, No. 6, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00926-4
the other in the normotensive WKY and WKY in which
hypertension was induced with L-NAME (Sigma Chemical
Co., St. Louis, Missouri), an inhibitor of nitric oxide
synthesis.
In the first experiment, the effects of four different doses
of rosuvastatin (Crestor) (AstraZeneca, Macclesfield,
Cheshire, England) on systemic and organ hemodynamics
and cardiovascular mass in SHR were studied. To this end,
male, 23-week-old SHR were randomly divided into five
groups, 15 rats in each. The control group did not receive
any treatment; rats in the other four groups were given
rosuvastatin daily by gavage, at 1, 5, 10, and 20 mg/kg dose
levels, respectively. Rosuvastatin was dissolved in distilled
water immediately before use and was administered within
the next one-half hour. Rats were treated for 12 weeks, and,
at the end, studies on systemic and regional hemodynamics
were performed as described in the following text.
The second experiment was performed in adult, 23-
week-old male WKY rats that were divided into four
groups, with 10 rats in each. The control group received no
treatment, whereas the second group was given rosuvastatin,
20 mg/kg/day by gavage. The third and fourth groups were
given L-NAME in drinking water, but, in addition, the
fourth group received rosuvastatin daily, 20 mg/kg. Initial
concentration of L-NAME in drinking water was 200 mg/l.
The concentration for each rat was then adjusted every
second day (based on fluid intake) so that the rats ingested
approximately 15 mg/kg/day of L-NAME throughout the
study. Treatment lasted for six weeks, and hemodynamic
studies were performed at the end.
Hemodynamic studies. At the end of treatment, the rats
were anesthetized with pentobarbital (40 mg/kg) and then
instrumented for the determination of systemic and regional
hemodynamics (using the reference standard radiomicro-
sphere method) as detailed elsewhere (17–19). In brief, a
jugular vein, femoral artery, and the left ventricle (via right
carotid artery) were cannulated with polyethylene catheters
(PE-50) filled with a heparinized 1% NaCl solution and
were exteriorized at the nape of the neck through a
subcutaneous tunnel. Rats were then placed into nonrestric-
tive polyethylene cages where they were allowed to recover
for 3 to 5 h (17–19).
The baseline measurements of systemic and coronary
hemodynamics were obtained while unrestrained, after full
recovery from anesthesia. Thus, the femoral arterial catheter
was connected to a pressure transducer (P23Db; Statham
Instruments, Oxnard, California), and arterial pressure was
recorded on a multichannel physiograph (Sensor Medics
R612, Yorba Linda, California) while, simultaneously, heart
rate was derived through a tachometer coupler. Cardiac
output was measured using the reference sample micro-
sphere method as reported previously (17–19). Cardiac
index was calculated from cardiac output and body weight
and expressed in ml/min/kg. Total peripheral resistance
index (U/kg) was calculated by dividing mean arterial
pressure by cardiac index. Blood flow to different organs
including heart, lungs, liver, kidneys, skeletal muscle, skin,
and brain was determined on the basis of percentage
distribution of the radiolabeled (113Sn) microspheres to
each organ at the end of the study (17–19). The method has
been validated previously (17).
After the baseline measurements were obtained, maximal
coronary vasodilation was produced by dipyridamole infu-
sion (4 mg/kg/min, intravenous for 10 min) (18,19) using a
Harvard infusion/withdrawal pump (Harvard Apparatus,
South Natick, Massachusetts). The hemodynamic studies
were repeated using microspheres having a second radionu-
clide (46Sc). At the conclusion of the study, rats were killed
with an overdose of pentobarbital, and, immediately there-
after, the heart, aorta, lungs, liver, kidneys, brain, and
samples of skin and skeletal muscle were removed and
weighed. Blood samples were taken for lipid profile mea-
surements. Tissue samples, as well as blood reference
samples, were placed in plastic scintillation vials and were
counted for 15 min in a deep-well gamma scintillation
spectrometer (Packard, Downer Grove, Illinois) having a
multichannel analyzer. Spillover correction between chan-
nels was achieved using matrix inversion software (Compu-
sphere, Packard, Downer Grove, Illinois). Organ blood
flows were calculated by multiplying the fractional distribu-
tion of radioactivity to each organ by cardiac output. They
were normalized for the wet weight of the respective organ
Table 1. BW, LWI, RVI, and AWI of Spontaneously Hypertensive Rats, Either Control or
Treated With 1, 5, 10, and 20 mg/kg/day of R
Indexes
Control
(n  12)
R 1 mg/kg
(n  14)
R 5 mg/kg
(n  13)
R 10 mg/kg
(n  13)
R 20 mg/kg
(n  13)
BW (g) 353  9 361  9 354  5 355  8 352  7
LWI (mg/g) 3.01  0.04 3.02  0.07 3.02  0.06 3.05  0.02 3.06  0.03
RWI (mg/g) 0.55  0.03 0.55  0.02 0.54  0.02 0.52  0.01 0.50  0.03
AWI (mg/mm) 1.23  0.03 1.22  0.03 1.23  0.02 1.17  0.03 1.21  0.02
Values are means  1 SEM.
AWI  aortic weight index; BW  body weight; LWI  left ventricular weight index; R  rosuvastatin; RVI  right
ventricular weight index.
Abbreviations and Acronyms
L-NAME  N-nitro-L-arginine
SHR  spontaneously hypertensive rats
WKY  Wistar-Kyoto rats
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and expressed as ml/min/g. Regional vascular resistances
were calculated by dividing the mean arterial pressure by the
respective organ blood flows and then normalized for that
organ weight (expressed as U/g). Blood flow reserve for the
right and left ventricles was calculated as the difference
between the baseline and dipyridamole infusion flows.
Minimal vascular resistance was defined as vascular resis-
tance achieved by dipyridamole.
Myocardial collagen content. As an estimate of collagen
content, hydroxyproline concentration was determined in
left ventricular samples, as described previously (18). Hy-
droxyproline concentration was expressed as mg/g dry
weight.
Statistical analysis. Values are expressed as the mean  1
SEM. The one-way analysis of variance and Bonferroni’s
modification of t test were used to test the significance of
differences between the groups (20). The 5% (or less)
confidence level was considered to be of statistical
significance.
RESULTS
Body, cardiac, and aortic masses in SHR. No differences
in body weight, left and right ventricular mass indexes, and
aortic mass index were found between groups (Table 1).
Table 2. SAP, DAP, MAP, HR, CI, and TPR in Spontaneously Hypertensive Rats, Either
Control or Treated With 1, 5, 10, and 20 mg/kg/day of R
Indexes
Control
(n  12)
R 1 mg/kg
(n  14)
R 5 mg/kg
(n  13)
R 10 mg/kg
(n  13)
R 20 mg/kg
(n  13)
SAP (mm Hg) 240  5 227  4 219  4* 215  5* 216  4*
DAP (mm Hg) 162  4 153  4 147  3* 133  6* 138  5*
MAP (mm Hg) 188  5 175  4 165  5* 157  5* 163  4*
HR (beats/min) 405  6 408  5 396  6 388  5 392  5
CI (ml/min/kg) 272  7 271  10 266  5 255  5 259  8
TPR (U/kg) 0.70  0.02 0.66  0.04 0.62  0.02* 0.59  0.03* 0.61  0.02*
Values are means  1 SEM. *p  0.05 when compared with control group.
CI  cardiac index; DAP  diastolic arterial pressure; HR  heart rate; MAP  mean arterial pressure; R  rosuvastatin;
SAP  systolic arterial pressure; TPR  total peripheral resistance.
Figure 1. Left ventricular coronary hemodynamics in control spontaneously hypertensive rats and rats treated with 1, 5, 10, or 20 mg/kg/day of rosuvastatin
for 12 weeks. Twelve to 14 rats per group. Values are means  1 SEM. *p  0.05 when compared with the value under basal conditions; p  0.05 when
compared with control group.
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Hydroxyproline concentration was determined in eight
untreated SHR and eight SHR given 10 mg/kg of rosuv-
astatin and, similarly, no difference was found (3.22 
0.21 mg/g in control vs. 3.11  0.18 in rosuvastatin-treated
rats).
Systemic hemodynamics in SHR. Rosuvastatin decreased
systolic, diastolic, and mean arterial pressures in a dose-
dependent manner up to the 10 mg/kg dose (Table 2). The
higher dose had no additional effects. Cardiac output and
heart rate were unaffected, but total peripheral resistance
was lower in rats treated with rosuvastatin (Table 2).
Coronary hemodynamics in SHR. Left ventricular coro-
nary hemodynamic indexes are presented in Figure 1.
Although rosuvastatin had no significant effect on baseline
blood flows or vascular resistances, it significantly increased
coronary flow reserve and decreased minimal coronary
vascular resistance. This effect appeared to be dose-
dependent, with a maximal effect being achieved at the 10
mg/kg level. Right ventricular coronary hemodynamics
paralleled those changes in the left ventricle (Fig. 2).
Other regional hemodynamics in SHR. The effects of
prolonged administration of rosuvastatin on blood flows and
vascular resistances in the kidney, liver, skin, skeletal muscle,
and brain are presented in Table 3. Rosuvastatin did not
affect basal flow or resistance in any of those organs.
However, it did decrease minimal vascular resistance in the
kidneys, muscle, and brain, but not in the liver and skin.
Lipid profile in SHR. Rosuvastatin treatment did not
affect plasma levels of total cholesterol, high-density lipopro-
tein, low-density lipoprotein, or triglycerides (Table 4).
Systemic and regional hemodynamics in WKY and WKY
given L-NAME. There were no hemodynamic changes
produced by rosuvastatin on systemic or coronary hemody-
namics in the normotensive WKY rats (Table 5). Six weeks
of treatment with L-NAME produced an increase in
arterial pressure and total peripheral resistance and a de-
crease in cardiac output in WKY. Simultaneously, a dete-
rioration of hemodynamic variables, as indicated by a
decrease in blood flows and increased vascular resistances,
occurred in all examined organs, including kidney, skin,
skeletal muscle, and heart. Of particular interest in these
L-NAME–treated rats was the finding that, although
rosuvastatin did not lower arterial pressure, it significantly
improved cardiac output, total peripheral resistance, and
regional hemodynamics. Left ventricular mass did not
increase in WKY rats treated with L-NAME (2.57  0.03
mg/g vs. 2.52  0.04 mg/g, in controls and L-NAME
WKY rats, respectively) nor did rosuvastatin affect left
ventricular mass in the L-NAME–treated rats (2.52  0.04
vs. 2.46  0.05, respectively).
Figure 2. Right ventricular coronary hemodynamics in control spontaneously hypertensive rats and rats treated with 1, 5, 10, or 20 mg/kg/day of
rosuvastatin for 12 weeks. Twelve to 14 rats per group. Values are means  1 SEM. *p  0.05 when compared with the value under basal conditions; p
 0.05 when compared with control group.
1094 Susic et al. JACC Vol. 42, No. 6, 2003
Pleiotropic Vascular Benefits of Statins September 17, 2003:1091–7
DISCUSSION
The results of this study clearly demonstrate that rosuvatatin
exerts beneficial cardiovascular effects in SHR, including
lowering of arterial pressure and peripheral resistance in a
dose-dependent manner. These hemodynamic changes
were independent of its lipid action. The pressure-lowering
effects of various statins have been reported previously in
angiotensin II-induced hypertension in rats (21), SHR rats
(22), as well as in hypertensive patients (23). In the present
study, the pressure-reducing effect of rosuvastatin in SHR
was mediated via a decrease in peripheral resistance, cardiac
output remaining unaffected. Interestingly, in the WKY rats
rendered hypertensive by L-NAME, rosuvastatin failed to
reduce arterial pressure but significantly reduced vascular
resistance. Simultaneously, rosuvastatin significantly im-
proved the L-NAME–induced decrease in cardiac output
and thereby kept pressure unchanged. Furthermore, it
appears that the beneficial effect of rosuvastatin on cardiac
output in the WKY/L-NAME rats was, at least in part,
mediated by improved coronary blood flow. Thus, coronary
blood flow was markedly decreased in rats treated with
L-NAME, which may have produced ventricular ischemia
with depression of systolic function and decreased cardiac
output. Rosuvastatin improved coronary flow, which may
have improved ventricular function and cardiac output in
these WKY/L-NAME rats. In addition, the rosuvastatin-
induced decrease in vascular resistance may have contrib-
uted to improvements in cardiac output by increasing
venous return.
Rosuvastatin reduced total peripheral vascular resistance
in both hypertensive models. Our results do not point to the
mechanism of this vasodilatory effect of rosuvastatin, but it
certainly is conceivable that an improvement in endothelial
function may mediate this action, particularly in the already
endothelial-compromised WKY/L-NAME rats (4–7,24).
Other mechanisms are also possible. Thus, some statins
have been shown to downregulate angiotensin II type 1
receptors in vascular smooth muscle (25), ameliorate angio-
tensin II-induced vascular injury (26), and increase nitric
oxide production in coronary vasculature (27). It is also
worth noting that rosuvastatin reduced minimal vascular
resistance (measured after infusion of a vasodilator) in all
organs examined with the exception of liver and skin. This
finding may indicate that regional differences in the vascular
effects of rosuvastatin may exist.
We have shown previously that coronary hemodynamics
are impaired in 35-week-old SHR; basal blood flow was
unaffected, but minimal coronary vascular resistance was
Table 3. BF and VR under Basal Conditions and MVR (After Dipyridamole Infusion) in
Kidney, Liver, Skin, Muscle, and Brain of SHR Rats, Either Control or Treated With 1, 5, 10,
and 20 mg/kg/day of R
Control
(n  12)
R 1 mg/kg
(n  14)
R 5 mg/kg
(n  13)
R 10 mg/kg
(n  13)
R 20 mg/kg
(n  13)
Kidney
BF (ml/min/g) 7.02  0.29 6.82  0.33 7.08  0.33 7.21  0.54 6.85  0.34
VR (U/g) 27.7  1.1 26.6  1.7 23.9  1.4 23.3  1.8 24.3  1.0
MVR (U/g) 23.7  1.2 17.4  0.7*† 16.8  1.0*† 15.3  0.8*† 16.6  0.8*†
Liver
BF (ml/min/g) 0.22  0.02 0.20  0.2 0.21  0.3 0.28  0.3 0.23  0.03
VR (U/g) 926  65 940  94 920  116 794  124 824  90
MVR (U/g) 781  147 746  99 620  66 622  169 703  125
Skin
BF (ml/min/g) 0.09  0.01 0.10  0.01 0.08  0.01 0.09  0.01 0.08  0.01
VR (U/g) 2,135  130 1,853  135 2,100  145 1,920  136 2,095  113
MVR (U/g) 2,306  165 1,892  114 2,332  210 2,075  142 2,112  153
Skeletal muscle
BF (ml/min/g) 0.10  0.01 0.11  0.02 0.10  0.01 0.10  0.01 0.10  0.01
VR (U/g) 2,111  187 2,056  244 1,861  131 1,725  101 1,827  136
MVR (U/g) 1,682  134 1,161  105*† 1,225  136*† 855  67*† 920  102*†
Brain
BF (ml/min/g) 0.97  0.03 0.99  0.07 1.00  0.08 1.11  0.08 1.00  0.07
VR (U/g) 197  7 190  16 176  14 153  13* 172  12
MVR (U/g) 183  8 155  12 144  11* 118  10* 133  8*
Values are means  1 SEM. *p  0.05 when compared with control group. †p  0.05 when compared with the value under
basal conditions.
BF  blood flow; MVR  minimal vascular resistance; R  rosuvastatin; SHR  spontaneously hypertensive rats; VR 
vascular resistance.
Table 4. Plasma Levels of Chol, HDL, LDL, or Trigl in
Control SHR and SHR Treated With 10 or 20 mg/kg/day of R
Control
(n  8)
R 10 mg/kg
(n  8)
R 20 mg/kg
(n  8)
Chol (mg/dl) 34  2 32  1 30  2
HDL (mg/dl) 15  1 18  1 16  1
LDL (mg/dl) 16  1 17  1 17  1
Trigl (mg/dl) 18  1 22  2 19  1
Values are means  1 SEM.
Chol  cholesterol; HDL  high-density lipoprotein; LDL  low-density
lipoprotein; R  rosuvastatin; SHR  spontaneously hypertensive rats; Trigl 
triglycerides.
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increased, and coronary flow reserve was decreased as
compared with normotensive WKY controls of the same
age (28). Our present findings confirm this observation.
Furthermore, the results show that rosuvastatin significantly
improved coronary hemodynamics by decreasing minimal
vascular resistance and increasing flow reserve in both
hypertensive models. It is conceivable that the improvement
in endothelial function (4–7,24), together with antioxidant
(10), and anti-inflammatory actions exerted by some statins,
may have contributed to that effect.
There was no effect of rosuvastatin on cardiovascular mass
in SHR. Thus, there was no difference in right or left
ventricular weight index, or aortic weight index between the
control and rosuvastatin-treated groups. Similarly, no effect
of rosuvastatin on ventricular collagen concentration was
observed in SHR. Furthermore, rosuvastatin did not affect
left ventricular mass in L-NAME–treated rats. These find-
ings are inconsistent with other studies in which statins have
been shown to reduce cardiac mass and ventricular collagen
concentration in rats with aortic stenosis (29), prevent
angiotensin II-induced cardiac myocyte hypertrophy in
tissue culture (30), and reduce collagen type 1 expression in
the hearts of rats with myocardial infarction (31). It is
possible that differences in properties of statins employed in
these studies account for the divergent results. Possibly a
more likely explanation would be that differences in exper-
imental models may be responsible for these divergent
findings. Thus, the antihypertrophic and antifibrotic effects
of some statins have been shown in angiotensin II-
dependent models (28–30), whereas the present study
involves models with naturally occurring or experimentally
induced endothelial dysfunction.
Study limitations. Our study is not devoid of potential
limitations. The doses of rosuvastatin used in the present
study were very high when compared with doses used in
human medicine. The most effective doses in our study (10
and 20 mg/kg/day) were 10 to 20  higher than the
maximal recommended dose in patients. Thus, one might
question the physiologic relevance of our findings. However,
it should be pointed out that, in general, doses of various
drugs used in rat studies are 50 to 100 times higher that
those used in human medicine. For instance, the effective
dose of hydrochlorothiazide in rats is 80 mg/kg versus about
1 mg/kg in patients; metoprolol dose in rats is 150 mg/kg
versus 1 to 2 mg/kg in patients; lisinopril dose in rats is 20
mg/kg versus 0.1 to 0.5 mg/kg in patients. Thus, by
inference, the fact that the dose of rosuvastatin was high
does not by itself abolish relevance of our data. It is also
worth noting that, although rosuvastatin did not affect
plasma cholesterol levels in our study, we cannot exclude the
possibility that the effects of rosuvastatin were mediated via
its effect on lipid metabolism.
Conclusions. In conclusion, our data demonstrated that
rosuvastatin reduced arterial pressure in genetic hyperten-
sion and improved systemic and regional hemodynamics in
the genetic model as well as in L-NAME–induced hyper-
tension independent of its lipid action. It seems likely that
this beneficial effect was mediated by amelioration of endo-
thelial dysfunction present in both experimental hyperten-
sive models, although other mechanisms are possible.
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